Ronald B DeMattos

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease
    David M Holtzman
    Center for the Study of Nervous System Injury, Washington University School of Medicine, St Louis, MO 63110, USA
    Adv Drug Deliv Rev 54:1603-13. 2002
  2. ncbi request reprint Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice
    Cynthia A Lemere
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 14:10-8. 2003
  3. ncbi request reprint ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo
    Ronald B DeMattos
    Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Neuron 41:193-202. 2004
  4. ncbi request reprint Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Eric Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biomark Med 4:81-9. 2010
  5. ncbi request reprint Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease
    Ronald B DeMattos
    Eli Lilly and Co, Lilly Research Laboratories, Neuroscience Discovery Research Indianapolis, IN 46285, USA
    J Mol Neurosci 23:255-62. 2004
  6. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007
  7. doi request reprint Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
  8. ncbi request reprint Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta
    Margaret M Racke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 25:629-36. 2005
  9. doi request reprint A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice
    Ronald B DeMattos
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuron 76:908-20. 2012
  10. ncbi request reprint Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
    Jean Cosme Dodart
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Nat Neurosci 5:452-7. 2002

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease
    David M Holtzman
    Center for the Study of Nervous System Injury, Washington University School of Medicine, St Louis, MO 63110, USA
    Adv Drug Deliv Rev 54:1603-13. 2002
    ..Abeta-related immune therapies in humans are an exciting new area of AD research. Understanding their detailed mechanism(s) of action and their potential usefulness awaits the results of future animal and human studies...
  2. ncbi request reprint Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice
    Cynthia A Lemere
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neurobiol Dis 14:10-8. 2003
    ..Most of the Abeta in the serum of the immunized mice was bound to antibodies. We conclude that following active immunization, anti-Abeta antibodies sequester serum Abeta and may increase central nervous system to serum Abeta clearance...
  3. ncbi request reprint ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo
    Ronald B DeMattos
    Neuroscience Discovery Research, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Neuron 41:193-202. 2004
    ..These findings demonstrate additive effects of apoE and clusterin on influencing Abeta deposition and that apoE plays an important role in regulating extracellular CNS Abeta metabolism independent of Abeta synthesis...
  4. ncbi request reprint Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Eric Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biomark Med 4:81-9. 2010
    ..Pivotal registration trials that rely on clinical measures as primary end points can utilize biochemical biomarkers as secondary outcomes indirectly measuring Alzheimer's disease pathology...
  5. ncbi request reprint Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease
    Ronald B DeMattos
    Eli Lilly and Co, Lilly Research Laboratories, Neuroscience Discovery Research Indianapolis, IN 46285, USA
    J Mol Neurosci 23:255-62. 2004
    ..These data indicate that apoE3 provides a dose-dependent protective effect against Abeta deposition. This study suggests that increasing human apoE levels in brain might be a possible therapeutic target for preventing AD...
  6. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007
    ..Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease...
  7. doi request reprint Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
    ..LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD...
  8. ncbi request reprint Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta
    Margaret M Racke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurosci 25:629-36. 2005
    ..These results may have important implications for future immune-based therapeutic strategies for Alzheimer's disease...
  9. doi request reprint A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice
    Ronald B DeMattos
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuron 76:908-20. 2012
    ..Mechanistic studies suggested that the lack of efficacy for 3D6 was attributed to poor target engagement in plaques. These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease...
  10. ncbi request reprint Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model
    Jean Cosme Dodart
    Neuroscience Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Nat Neurosci 5:452-7. 2002
    ....
  11. ncbi request reprint A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes
    Yu Liang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurochem 88:623-34. 2004
    ..LXR/RXR agonists may have significant impact on the pathogenesis of multiple neurological diseases, including AD...
  12. ncbi request reprint Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease
    Ronald B DeMattos
    Center for the Study of Nervous System Injury, Alzheimer s Disease Research Center, Department of Neurology, Molecular Biology and Pharmacology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, MO 63110, USA
    Science 295:2264-7. 2002
    ..This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD...
  13. doi request reprint ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo
    Braydon L Burgess
    Department of Pathology and Laboratory Medicine, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    J Lipid Res 49:1254-67. 2008
    ....
  14. ncbi request reprint Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease
    Ronald B DeMattos
    Center for the Study of Nervous System Injury, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Neurochem 81:229-36. 2002
    ..These findings suggest that there is a dynamic equilibrium between CNS and plasma Abeta, and that plaques create a new equilibrium because soluble CNS Abeta not only enters the plasma but also deposits onto amyloid plaques in the CNS...
  15. ncbi request reprint The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice
    John D Fryer
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 280:25754-9. 2005
    ....
  16. ncbi request reprint Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta
    Masayuki Morikawa
    Department of Neurology, Washington University School of Medicine, St Louis, MO 63130, USA
    Neurobiol Dis 19:66-76. 2005
    ..These immortalized astrocytes will be useful for studying mechanisms underlying the isoform-specific effects of apoE in the CNS...
  17. pmc Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease
    Ronald B DeMattos
    Center for the Study of Nervous System Injury, Alzheimer s Disease Research Center, and Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, MO 63110, USA
    Proc Natl Acad Sci U S A 99:10843-8. 2002
    ..These findings demonstrate that clusterin markedly influences Abeta structure and neuritic toxicity in vivo and is likely to play an important role in Alzheimer's disease pathogenesis...
  18. ncbi request reprint Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice
    John D Fryer
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Neurosci 23:7889-96. 2003
    ..These findings demonstrate that murine apoE markedly promotes the formation of CAA and associated vessel damage and that the effect of apoE combined with the level of Abeta40 or the ratio of Abeta 40:42 facilitates this process...
  19. ncbi request reprint In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life
    John R Cirrito
    Department of Neurology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Neurosci 23:8844-53. 2003
    ..This now measurable in vivo pool is a likely target for new diagnostic and therapeutic strategies...
  20. ncbi request reprint In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins
    Justin Legleiter
    Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA 15213, USA
    J Colloid Interface Sci 278:96-106. 2004
    ..This study and the developed AFM methodologies open the way to further in situ AFM studies of the lipoproteins in general and more specifically of CNS lipoproteins...
  21. ncbi request reprint The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein
    Gavin H Tansley
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    J Lipid Res 48:1022-34. 2007
    ..These findings suggest that altered cholesterol metabolism and APP trafficking mediated by ABCG1 may contribute to the accelerated onset of AD neuropathology in DS...
  22. ncbi request reprint Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy
    Justin Legleiter
    Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA 15213, USA
    J Mol Biol 335:997-1006. 2004
    ....